Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Grace Winship"'
Autor:
Meng X He, Jake Conway, Eric P. Winer, Geoffrey I. Shapiro, Bose Kochupurakkal, Ricardo G. Pastorello, Chelsea Andrews, Lorenzo Trippa, Eliezer M. Van Allen, Robert Godin, Beth Overmoyer, Elizabeth A. Mittendorf, Rie K. Tahara, Wafa Osmani, Tanya Keenan, Jennifer L. Guerriero, Sara M. Tolaney, Grace Winship, Zhenying Tan-Wasielewski, Adam Tracy
Publikováno v:
Cancer Research. 80:P3-10
Introduction: mTNBC progresses rapidly on first-line chemotherapy. For instance, in the TNT trial, median progression-free survival (PFS) was 3 months on first-line carboplatin. Selective inhibition of Wee1, a negative regulator of the G2 cell cycle
Autor:
Tianyu Li, Wafa Osmani, Sara M. Tolaney, Lorenzo Trippa, Beth Overmoyer, Eric P. Winer, Tanya Keenan, Chelsea Andrews, Romualdo Barroso-Sousa, Grace Winship, Elizabeth A. Mittendorf, Dan G. Duda
Publikováno v:
Cancer Research. 80:P3-09
Background: Patients (pts) with mTNBC have a poor prognosis, and new therapies are needed. Cabozantinib is a multikinase inhibitor that blocks VEGF receptor 2, reduces myeloid-derived suppressor cells, and increases T cell infiltration, suggesting it
Autor:
H Parsons, Emily Schlosnagle, Jiani Hu, Grace Winship, Faina Nakhlis, Nicholas Johnson, Shom Goel, Meredith M. Regan, Beth T. Harrison, Jennifer L. Guerriero, Beth Overmoyer, Sonia Pernas, LA Chichester, Elizabeth A. Mittendorf
Publikováno v:
Cancer Research. 79:PD3-08
Background: Inflammatory breast cancer (IBC) is an aggressive form of breast cancer that remains relatively understudied. We examined the efficacy of neoadjuvant dual-HER2 blockade (trastuzumab (H) and pertuzumab (P)) combined with paclitaxel (T) in
Autor:
Jim C. Hu, Meredith M. Regan, Beth T. Harrison, Jennifer L. Guerriero, Grace Winship, Sonia Pernas, Nathan Johnson, Shom Goel, Elizabeth A. Mittendorf, Beth Overmoyer, A. Sokolov
Publikováno v:
Annals of Oncology. 30:v37
Background Inflammatory breast cancer (IBC) is an understudied form of breast cancer (BC). The incidence of HER2-positive disease in IBC is 2-fold greater than that in non-IBC. Several studies evaluating dual-HER2 blockade in HER2-positive BC have de
Autor:
Grace Winship, Romualdo Barroso-Sousa, Dan G. Duda, Hao Guo, Beth Overmoyer, William T. Barry, Sara M. Tolaney
Publikováno v:
Journal of Clinical Oncology. 36:TPS1119-TPS1119
TPS1119Background: Patients with mTNBC have a poor prognosis, and new therapies are needed. Vascular endothelial growth factor (VEGF)-A and myeloid-derived suppressors cells (MDSCs) have been recog...